{"slug":"tesamorelin-postherpetic","verification":{"valid":true,"entries":2,"head":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"},"energy":{"passes":2,"tokens_in":28024,"tokens_out":2600,"tokens_total":30624,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"},"provenance":[{"ts":"2026-06-29T23:15:59.416Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Postherpetic\nSlug: tesamorelin-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pe","response":"{\n  \"slug\": \"tesamorelin-postherpetic\",\n  \"title\": \"Tesamorelin for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia (PHN) follows shingles (herpes zoster) reactivation of varicella-zoster virus. Nerve damage occurs in affected dermatomes. Axons degenerate. Myelin sheaths suffer. Distal tissues lose innervation. Muscle atrophy can follow if reinnervation lags. Chronic pain persists because repair pathways fail to restore normal signaling. This is degeneration outrunning repair at the peripheral nerve level.\\n\\n## Why Tesamorelin might help you\\n\\nTesamorelin stimulates growth hormone release via the GH axis. If your postherpetic issue includes failed axonal regeneration or muscle atrophy from denervation, this layer matters.\\n\\n1. GH and IGF-1 signaling support Schwann cell activity and axon growth in nerve injury models.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n3. Reduced visceral fat is a separate documented effect but not directly tied to neural recovery here.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin maps to the GH axis / visceral fat layer. If your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n\\n- **Tesamorelin** → GH axis / visceral fat\\n\\n## What the evidence actually shows\\n\\nNo human trials test tesamorelin specifically in postherpetic neuralgia (preclinical|mechanistic). One ongoing Phase 2 trial (NCT03150511) evaluates tesamorelin after peripheral nerve injury repair in humans; outcomes include axonal regeneration via MRI/EMG and functional recovery. Results remain unpublished as of 2026 (human|ongoing).\\n\\nAnimal studies show growth hormone improves sciatic nerve regeneration after transection in rats: increased axon and Schwann cell density, higher compound muscle action potential amplitude, and bette","tokens_in":28024,"tokens_out":2600,"cost":0,"prev":"genesis","hash":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b"},{"ts":"2026-07-17T02:42:25.507Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-postherpetic","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6043c17c1a0ea584e53d729c9f9c0d8b6cdc25ed33e58c8867ac7027e45a6a6b","hash":"bc4c6e4e64b228f9121e5a89e74158b5c7616fb7e31d27f3b1f18df1e1295ab4"}]}